Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome.
The authors prospectively evaluated 67 consecutive patients with the acquired immune deficiency syndrome (AIDS) and cytomegalovirus (CMV) retinitis during a 33-month period to assess the clinical patterns of retinal infection, efficacy of treatment, long-term survival, and relationship of retinitis to immune function. Immediately sight-threatening retinitis presented in six patients (9%) with peripapillary disease; primary foveal infection was not observed. Eighty-seven percent of patients were treated with ganciclovir. Thirty-nine patients (58%) presented with unilateral disease and contralateral infection developed in 15% of those while on ganciclovir. Smoldering (incompletely responsive) retinitis was seen in 33% of the 21 patients whose retinitis progressed while receiving ganciclovir. Progression of treated retinitis was associated with a lower lymphocyte count (P = 0.04). Median survival after diagnosis of CMV retinitis was 8 months. This represents the largest reported prospective study of CMV retinitis and indicates that (1) CMV infrequently poses an immediate threat to vision on presentation, (2) response to therapy may be related to immune function, and (3) smoldering retinitis should be recognized as an important clinical entity associated with treatment failure.
Gross
J G
JG
Department of Ophthalmology, University of California San Diego School of Medicine.
Bozzette
S A
SA
Mathews
W C
WC
Spector
S A
SA
Abramson
I S
IS
McCutchan
J A
JA
Mendez
T
T
Munguia
D
D
Freeman
W R
WR
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D005260:Female; D005654:Fundus Oculi; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D007958:Leukocyte Count; D008137:Longitudinal Studies; D008297:Male; D011446:Prospective Studies; D012173:Retinitis / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D013534:Survival; D014792:Visual Acuity
D015774:Ganciclovir